⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121126 | 0.82 | — | — | |
| Ammonia Solution, Strong SCHEMBL30449543 | 0.76 | CA1 (0.30) | — | |
| SCHEMBL27882303 | 0.76 | — | — | |
| SCHEMBL28298957 | 0.76 | — | — | |
| Iodide SCHEMBL2788357 | 0.76 | — | — | |
| SCHEMBL17140368 | 0.76 | — | — | |
| Hydrogen Sulfide SCHEMBL9633068 | 0.76 | — | — | |
| SCHEMBL2128461 | 0.76 | — | — | |
| Fluoride SCHEMBL27602730 | 0.76 | — | — | |
| SCHEMBL28238441 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110291089-A | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2019-09-27 | — | — | CN | claimed |
| CN-105829287-B | The active bridged piperazine derivatives of multiplex mode with anti-pain | 埃斯蒂文制药股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| CN-104284891-B | Conformationally constrained, fully synthetic macrocyclic compounds | 波利弗尔股份公司 | 2018-04-17 | — | — | CN | claimed |
| CN-105324379-B | Benzimidazole derivatives as bromodomain inhibitors | 吉利德科学公司 | 2018-12-04 | — | — | CN | disclosed |
| CN-105263490-B | Substituted triazolopyridines and methods of use | 基因泰克公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-107428749-A | The substituted ylamine compounds of imidazo [1,2 α] pyridine 2 and its pharmaceutical composition and application method | 南京泽宁医药研发有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-106794126-A | topical formulations | 艾伯维公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-103145715-B | Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors | F·霍夫曼-罗须公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |